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Abstract: The broad application of RNA interference for disease prevention is dependent upon the 
production of dsRNA in an economically feasible, scalable, and sustainable fashion, as well as the 
identification of safe and effective methods for RNA delivery. Current research has sparked interest in 
the use of Saccharomyces cerevisiae for these applications. This review examines the potential for 
commercial development of yeast interfering RNA expression and delivery systems. S. cerevisiae is a 
genetic model organism that lacks a functional RNA interference system, which may make it an ideal 
system for expression and accumulation of high levels of recombinant interfering RNA. Moreover, re-
cent studies in a variety of eukaryotic species suggest that this microbe may be an excellent and safe 
system for interfering RNA delivery. Key areas for further research and development include optimi-
zation of interfering RNA expression in S. cerevisiae, industrial-sized scaling of recombinant yeast 
cultures in which interfering RNA molecules are expressed, the development of methods for large-
scale drying of yeast that preserve interfering RNA integrity, and identification of encapsulating 
agents that promote yeast stability in various environmental conditions. The genetic tractability of S. 
cerevisiae and a long history of using this microbe in both the food and pharmaceutical industry will 
facilitate further development of this promising new technology, which has many potential applica-
tions of medical importance. 
Keywords: RNAi, shRNA, gene therapy, Aedes aegypti, Anopheles gambiae, mosquito, biopharmaceutical, bioengineering. 
1. INTRODUCTION 
 Saccharomyces cerevisiae, also known as baker’s or 
budding yeast, is a non-infectious microbe and genetic 
model organism. Research in S. cerevisiae has provided key 
insights into the regulation of many fundamental eukaryotic 
cellular processes, including the cell cycle, signal transduc-
tion, chromatin structure, transcription, and genetic inheri-
tance [1, 2]. Despite the many attributes of this model sys-
tem, RNA interference (RNAi), a regulatory pathway in eu-
karyotic cells that silences gene expression through the pro-
duction of small interfering RNAs (siRNAs), has not tradi-
tionally been studied in S. cerevisiae [1], which lacks com-
ponents of the RNAi pathway [3]. RNAi is an ancient 
mechanism that protects a diverse number of eukaryotic spe-
cies, including some species of yeast [1, 3], from nucleic 
acids such as viruses [4]. The presence of double stranded 
RNA (dsRNA) in a cell triggers processing of the dsRNA by 
Dicer, a ribonuclease III (RNAse III) family endonuclease. 
Dicer cleaves dsRNA molecules into siRNAs, which are 
then assembled onto the Argonaute effector protein [5]. This 
results in complementary base pairing interactions that target 
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and inactivate endogenous cellular RNAs or repress tran-
scription [6, 7].  
 The potential applications of RNAi for the treatment 
and prevention of various diseases are seemingly endless. 
As discussed by Tam et al. [8], siRNAs can suppress viral 
infections, tumorigenesis, inflammatory disorders, and car-
diovascular disease. Furthermore, RNAi could potentially 
be used for the control of human disease vector insects [9, 
10]. The broad application of RNAi for applications of 
medical and commercial importance is dependent upon 
production of dsRNA in an economically feasible, scalable, 
and sustainable fashion. dsRNA manufacture has tradition-
ally relied on expensive, carbon-intensive chemical synthe-
sis, resulting in high costs that have made the broad and 
large-scale use of dsRNA prohibitively expensive [11]. In 
addition to advancements in the cost-effective scalable 
manufacture of interfering RNA, broad application of 
RNAi requires not only the discovery of molecules to be 
used in various applications but also safe and effective 
mechanisms for their delivery to humans or other intended 
organisms [12]. Several studies in which S. cerevisiae was 
successfully used as an expression and delivery system for 
dsRNA to other organisms [9, 10, 13, 14] have sparked 
interest in the use of S. cerevisiae for RNAi-based applica-
tions (Table 1).  
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2. ADVANTAGES OF THE S. CEREVISIAE EXPRES-
SION SYSTEM 
 A deficiency of functional RNAi machinery in S. cere-
visiae, which lacks both Dicer and Argonaute [3], may have 
initially caused it to be overlooked as a system for producing 
interfering RNA molecules. However, this lack of RNAi 
machinery may, in fact, promote the accumulation of bioen-
gineered dsRNAs in yeasts, making it an ideal system for 
RNA production. In support of this concept, recent studies in 
plants suggest that dsRNAs can be stably produced in chlo-
roplasts, a cellular component that, like yeast, lacks func-
tional RNAi machinery [18]. When insecticidal dsRNA tar-
geting potato beetles was expressed in the chloroplasts of 
potato plants, the plants were better protected from this crop 
pest than plants in which dsRNA had been expressed from 
the potato plant nuclear genome. Expression of dsRNA in 
chloroplasts led to accumulation of dsRNA at high levels, up 
to 0.4% of total cellular RNA. These findings, which have 
generated interest in using the chloroplast genome to express 
dsRNAs targeting crop pests [18], may be applicable to yeast 
dsRNA expression systems. 
 A number of key advantages make S. cerevisiae an excel-
lent system for expression of recombinant nucleic acids and 
proteins [2]. First, S. cerevisiae grows rapidly and is both 
straightforward and inexpensive to culture. As discussed by 
Roohvan et al. [2], sophisticated genetic manipulations are 
possible in S. cerevisiae, the first eukaryotic genome to be 
sequenced [19]. A wide variety of vectors, including episo-
mal, integrative, and copy number controlled vectors are 
available, as are a wide range of auxotrophic strains that can 
be rescued through transformation with vectors bearing wild-
type copies of the mutated genes. Moreover, a number of 
different promoters, including both constitutive and induc-
ible promoters, are available, permitting flexibility in the 
construction of gene expression systems. Although genetic 
manipulations in S. cerevisiae are as straightforward as pro-
karyotic systems, the advanced cellular features of eukaryo-
tes, including post-translational modifications and glycosyla-
tion patterns that are more comparable to mammals, exist in 
yeast [2]. S. cerevisiae has also been genetically engineered 
such that it can generate proteins with more human-like gly-
cosylation patterns, thereby allowing for the production of 
recombinant proteins that are properly processed in humans 
[20]. Furthermore, yeasts can be engineered to secrete re-
combinant proteins into the cell media, which greatly facili-
tates subsequent purification of these proteins, another key 
advantage of using yeast expression systems [21]. Relatively 
high levels of recombinant protein expression, more than 1 
g/L [2], have been obtained for several products. Finally, 
fermentation and downstream processing systems have been 
established for S. cerevisiae [2]. The many attributes of S. 
cerevisiae suggest that it could be an excellent system for 
scaled expression of recombinant interfering RNA mole-
cules. 
 Regardless of whether the end goal is gene therapy, mos-
quito control, or crop protection, the successful application 
of RNAi requires the development of safe and effective de-
livery systems. The use of bacterial and viral dsRNA deliv-
ery systems presents safety risks, as non-infectious agents 
and means of ensuring that the recombinant DNA does not 
integrate into the genome of the target organism are pre-
ferred [13]. The safety profile of S. cerevisiae makes it a 
winner in these regards, as well [2]. In three recent studies 
[9, 10, 13], S. cerevisiae was genetically engineered to ex-
press short hairpin RNA (shRNA), an artificial RNA mole-
cule with a hairpin turn that can be used for RNAi. In these 
studies, the yeast strains were engineered for expression of 
shRNA corresponding to murine [13] and mosquito [9, 10] 
genes. The subsequent feeding of these engineered yeast 
strains to mice and mosquito larvae resulted in effective gene 
silencing in these organisms. It was further demonstrated 
that shRNA expression cassettes can be stably integrated into 
the yeast genome [9], and that the yeast can be heat-
inactivated prior to use in oral feeding assays [9, 10], thereby 
alleviating additional safety concerns. The results of these 
studies, which will be described in more detail below, sug-
gest that use of this technology has a wide range of potential 
Table 1. Bioengineering S. cerevisiae for recombinant interfering RNA expression. 
Recombinant Yeast Strains Generated Resulting Advancements 
Restoration of Dicer and Argonaut activity in S. cerevisiaea Functional RNAi activity in yeast. 
Generation of recombinant S. cerevisiae for delivery of shRNA 
targeting murine CD40b 
Successful delivery of an shRNA expression system to murine intestinal DC cells, 
leading to successful gene silencing in mice. 
S. cerevisiae expressing shRNA corresponding to mosquito 
genesc 
Successful delivery of dried inactivated yeast interfering RNA pesticides to mosqui-
toes; shRNA expression cassette successfully integrated into yeast genome.  
S. cerevisiae that express long dsRNA molecules targeting 
Drosophila crop pestsd 
Development of S. cerevisiae system for expressing and delivering long dsRNA insec-
ticides to crop pests  
S. cerevisiae shRNA expression system for improvement of 
itaconic acid production straine  
Optimization of a yeast strain as a metabolic engineering tool; evaluation of parameters 
that improve shRNA expression 
RNAi screening libraries generatedf Facilitated development of tunable yeast biomolecule production systems; evaluation 
of parameters that improve expression of long dsRNA molecules in S. cerevisiae 
Key advancements resulting from the generation of yeast strains expressing recombinant interfering RNA molecules are noted here and discussed in further detail in this review.  
aReference [3]; bReference [13] ; cReferences [9, 10]} ; dReference [14]; eReference [15]; fReferences [16, 17]. 
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medical applications, from therapeutics in humans to the 
control of human disease vector mosquitoes (Table 1). In 
addition to discussing potential applications, this review 
summarizes requisite research and development that will 
facilitate the commercialization of this technology.   
3. POTENTIAL APPLICATIONS 
3.1. A Yeast System for Delivery of shRNA to Mammals 
 S. cerevisiase has been investigated as a potential vaccine 
carrier, as its complex cell wall components and appropriate 
size facilitate the specific uptake of this microbe by Den-
dritic Cells (DCs) [22], professional antigen-presenting cells 
that function in innate and adaptive immune responses [23-
25]. Importantly, S. cerevisiae appears to withstand simu-
lated human digestive environment conditions, suggesting 
that it may be a useful oral delivery system for biological 
molecules to intestinal DC cells [26]. Recognition of S. cere-
visiae through dectin, mannose-fucose, and toll-like recep-
tors on DC cells permits the phagocytosis of yeast by these 
cells, resulting in DC maturation [27-29]. DNA and mRNA 
have been successfully delivered to mammalian phagocytic 
cells using a recombinant yeast delivery system [30]. S. cer-
evisiae has also been utilized for the successful delivery of 
DNA and protein to DCs [27, 31, 32]. Based on these obser-
vations, Zhang et al. [13] hypothesized that S. cerevisiae 
might serve as a potential oral delivery system for shRNA to 
mouse intestinal DCs (Table 1).  
 To test their hypothesis, Zhang et al. [13] chose to si-
lence CD40, an activation receptor [33] that functions in DC 
maturation [34], the inhibition of which was expected to im-
pact the immune response. shRNA corresponding to the se-
quence of CD40 was expressed in recombinant S. cerevisiae. 
For the construction of the expression vector, the shRNA 
expression cassette was placed under control of a mammal-
ian U6 promoter followed by a small nuclear RNA leader 
sequence. This shRNA targeting sequence was inserted into 
an endogenous mouse micro RNA (miRNA), miR30 [35-37]. 
The authors anticipated that DC cells would take up the re-
combinant yeast through phagocytosis, after which the 
shRNA expression vector would be taken into the murine 
nucleus where shRNA would be transcribed. Following 
shRNA processing, mature siRNA was expected to promote 
CD40 mRNA degradation [13].  
 To verify the function of the shRNA expression vector, it 
was transfected into a cultured mammalian cell line with a 
CD40-GFP reporter. GFP expression was reduced, confirm-
ing that shRNA had been successfully produced and had 
effectively silenced the reporter transcript. shRNA expres-
sion was also confirmed through reverse transcription of 
total RNA from the cells and PCR amplification of DNA 
corresponding to the shRNA. Mice were then fed with either 
recombinant yeast expressing the shRNA or control yeast 
bearing a vector that lacked the shRNA expression cassette. 
Animals fed with yeast expressing shRNA displayed reduced 
CD40 levels in intestinal dendritic cells. Analysis of mouse 
serum demonstrated that CD40 silencing resulted in altered 
cytokine levels. The results of this investigation suggested 
that a recombinant yeast delivery system could be used for 
efficient delivery of an shRNA expression system to murine 
dendritic cells for the purpose of gene silencing and immu-
nomodulation. Zhang et al. [13] commented that the effec-
tive silencing of CD40 in humans could have therapeutic 
applications for the treatment of various autoimmune disor-
ders, vascular disease, and rejection of transplanted tissues. 
This group also published a protocol with detailed instruc-
tions for the construction of shRNA expression vectors and 
delivery of recombinant yeast through oral administration to 
mice [38]. Their publication of detailed methodology will 
hopefully permit other researchers to explore the use of this 
delivery system for additional applications. 
3.2. Targeting of Disease Vector Mosquitoes with Yeast 
Interfering RNA Pesticides 
 Although it is beginning to attract attention in agricul-
tural biotechnology communities [18], the use of RNA inter-
ference (RNAi) is an innovative yet still largely unexplored 
approach for control of disease vector mosquitoes. Over 3 
billion people worldwide are at risk for contracting malaria, 
which results from infection with Plasmodium spp. parasites 
that are transmitted to humans through the bites of infected 
Anopheles mosquitoes [39]. In 2016, there were >200 mil-
lion cases of malaria world-wide, and 445,000 deaths re-
sulted from malaria infection [39]. Dengue, a leading cause 
of morbidity in the tropics, Zika, which was designated a 
public health emergency of international concern in 2016, as 
well as yellow fever and chikungunya, result from infections 
with arboviruses transmitted through the bites of Aedes mos-
quitoes [40]. Cases of Zika, which has been linked to severe 
birth defects and neurological disorders, are currently occur-
ring in many countries in the Americas, and Zika has rapidly 
spread to previously unaffected geographic areas [41]. Den-
gue has an annual incidence of approximately 400 million 
cases resulting in ~50,000 deaths annually worldwide [42]. 
These statistics highlight the vital need to combat these 
pathogens and the mosquitoes that transmit them to human 
hosts. Due to the lack of progress in vaccine development, 
production and distribution, mosquito control is the primary 
means of controlling mosquito-borne illnesses. However, 
increased emergence of insecticide resistance and a general 
lack of funding for and support of mosquito control pro-
grams threaten current strategies for managing mosquitoes 
[40]. Larviciding, the application of microbial or chemical 
agents to kill mosquito larvae in aquatic habitats, is a key 
component of integrated mosquito control and disease pre-
vention strategies. Aedes mosquitoes lay eggs in natural and 
artificial water-filled containers within or close to human 
dwellings in urban areas, and are therefore susceptible to 
larviciding [43]. When used as a supplement to insecticide 
treated nets and indoor residual spraying, larviciding is cost-
effective for control of Anopheles (malaria vector) mosqui-
toes in urban settings where vector breeding sites are few, 
fixed, and findable [44]. Given the increase of reported in-
secticide resistance to existing larvicides and the rising con-
cern for negative effects of pesticides on non-target organ-
isms, new larvicidal agents are vitally needed to address cur-
rent and emerging arthropod-borne infectious diseases. To 
this end, we have pursued RNAi approaches for the control 
of mosquito larvae [9, 10, 45-48]. 
 Though most mosquito researchers use longer (300-400 
bp) dsRNA molecules for RNAi, the short length (25 bp) of 
custom siRNAs and their shRNA counterparts facilitates the 
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design of interfering RNA that recognizes conserved target 
sites in multiple mosquito species, but not in non-target or-
ganisms. We initiated high-throughput screens designed to 
enrich for the selection of siRNA larvicides that generate 
high levels of mosquito mortality and that can be used 
against multiple disease vector mosquito species, but which 
lack sequence homology in non-targeted species. Our goal is 
to create an siRNA arsenal that can combat pesticide resis-
tance that arises from point mutations in any one mosquito 
gene target sequence. These screens led to the discovery of 
hundreds of siRNAs that induce mosquito larval lethality [9, 
10]. To facilitate the cost-effective production of interfering 
RNA and delivery of RNA pesticides to mosquitoes in the 
field, S. cerevisiae was engineered to produce shRNA corre-
sponding to select genes/target sequences identified in the 
siRNA larvicide screens [9, 10] (Table 1).  
 shRNA expression cassettes corresponding to several 
siRNA targets sequences in Aedes [9] and Anopheles [10] 
genes were cloned into the non-integrating pRS426 GPD 
yeast shuttle vector [49]. This multi-copy shuttle plasmid 
was transformed into S. cerevisiae, facilitating expression of 
shRNA downstream of a constitutive GPD promoter [49]. 
These yeast strains, as well as a control yeast strain express-
ing shRNA with no known target in mosquitoes, were ini-
tially fed to larvae in an agarose gel-covered formulation 
containing live yeast, and this formulation generated high 
levels of larval death. It was determined that heat-killed 
yeast prepared in a dry pellet formulation killed larvae as 
effectively as the live yeast formulation. Dried and inacti-
vated yeast interfering RNA pellets generated >90% silenc-
ing of target genes and up to 100% larval lethality in labora-
tory trials [9, 10]. In our hands, the yeast interfering RNA 
delivery strategy is the most effective method for gene si-
lencing in mosquito larvae that we have tested to date and 
generates higher levels of larval mortality than other delivery 
methods examined in our laboratory.   
 Upon verification that these yeast strains induced signifi-
cant larval lethality, stable yeast transformants were gener-
ated for several strains of interest [9]. In these strains, the 
shRNA expression cassette was placed under control of an 
inducible Gal1 promoter, which facilitates induction of 
shRNA expression with galactose just prior to harvesting and 
heat killing of the yeast for generation of inactivated yeast 
tablets. Moreover, for these strains, two copies of shRNA 
expression cassettes were integrated into the yeast genome, 
dispensing of the use of plasmids with antibiotic resistance 
markers and eliminating the risk of horizontal transfer to 
other species, two modifications that will facilitate the test-
ing of these yeast strains in field trials [9]. Semi-field trials 
with the yeast larvicides are underway. The development of 
dried inactivated ready-to-use yeast interfering RNA pellets 
will facilitate the seamless integration of this technology into 
existing mosquito control programs. Importantly, interfering 
RNA is generated through yeast culturing, significantly re-
ducing RNA production costs. Moreover, yeasts have been 
cultivated worldwide for thousands of years, and this tech-
nology can be adapted to resource-limited countries with 
constrained infrastructures. Dried yeast can be packaged and 
shipped, which can facilitate regional distribution to com-
munities in need. Furthermore, S. cerevisiae, a natural prod-
uct that is often used in food and alcoholic beverage prepara-
tion and sold (in its inactivated form) as a dietary supple-
ment, is non-toxic, suggesting that it could be much safer for 
humans than existing chemical pesticides. Finally, this tech-
nology is scalable, as yeast can be produced in industrial-
sized cultures [9, 10].  
 Our characterization and development of mosquito yeast 
interfering RNA larvicides revealed several findings that 
may be of importance to those working to develop yeast as a 
delivery system for human therapeutics. First, as discussed 
above, laboratory trials demonstrate that the larvicidal capac-
ity of this yeast is maintained even when the microbes are 
heat-killed and inactivated [9, 10]. Given that consumption 
of large quantities of live yeast is typically not advised, it 
would be preferable to heat-inactivate yeast used in human 
therapies. Indeed, most studies with Whole Yeast Vaccines 
(WYVs) use heat-killed vaccines as opposed to live yeast 
[28]. Moreover, while Zhang et al. [13] prepared shRNA 
expression cassettes that would be delivered to and ex-
pressed in murine cells, we instead induced shRNA expres-
sion in yeast from transgenes integrated into the yeast ge-
nome, heat-killed the yeast, and then delivered this shRNA 
to insects in yeast cells. This shRNA, which was only pro-
duced in yeast rather than in insect cells, effectively sup-
pressed insect gene expression. A similar procedure may be 
a viable option in mice or humans, and it would be interest-
ing to directly compare the levels of CD40 silencing that 
result from use of the two different systems in the mouse 
system. Furthermore, we succeeded in the development of 
dried inactivated ready to use yeast interfering RNA pellets. 
These pellets were modeled after nutritional yeast, a human 
dietary supplement. This dried pellet formulation could 
therefore be suitable for human consumption.  
3.3. Mass Production and Purification of Interfering 
RNA 
 While it may be beneficial to use yeast as a delivery sys-
tem, the development of yeast systems for large-scale pro-
duction of interfering RNA that could be subsequently puri-
fied would also be of interest. To date, microbial dsRNA 
expression systems have focused on the development of bac-
terial systems for dsRNA expression. In fact, shortly after 
the discovery of RNA silencing in Caenorhabditis elegans 
[50], an Escherichia coli dsRNA expression and delivery 
system was developed [51]. In the bacterial system, frag-
ments of the gene to be silenced are flanked by opposing T7 
RNA polymerase promoters, allowing for the production of 
dsRNA molecules. dsRNA expression is improved by trans-
formation of E. coli strains lacking RNAse III [51], which 
permits higher levels of dsRNA accumulation. Even larger 
quantities of dsRNA can be produced in RNAse III deficient 
E. coli that overexpress T7 polymerase [52]. 
 Huang et al. [53] later developed a method for mass pro-
duction of siRNA in E. coli that capitalizes on expression of 
the siRNA binding protein p19. Expression of recombinant 
His-tagged p19 protein stabilized siRNA that was produced 
in the E. coli while also facilitating subsequent nickel-
column purification of the siRNA [54]. This system was re-
cently further optimized, and production was successfully 
scaled using a high-cell density fed-batch fermentation 
method in a bioreactor [55]. This system generated 10 mg 
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purified RNA yields, yields that were significantly higher 
than those achieved in other bacterial systems. Interestingly, 
the authors found that production of hairpin RNA constructs 
resulted in higher yields, higher percentages of the target 
sequence, and better silencing efficiencies than siRNAs that 
were generated with convergent overlapping sense and an-
tisense transcripts. Two convergent T7 promoters flanking 
hairpin RNA could further increase siRNA production. The 
authors concluded that this method could be adapted for pro-
duction of siRNAs in a renewable and cost-effective manner, 
though they expect that this will require further process de-
velopment. In particular, they noted that there would be a 
need for further purification to reduce levels of contaminat-
ing dsRNAs present in the bacteria [55].  
 Surprisingly, large-scale interfering RNA production 
systems in S. cerevisiae have yet to be described in the litera-
ture, perhaps once again as a result of the lack of functional 
RNAi machinery in S. cerevisiae. However, as discussed 
above, it is possible that this lack of RNAi machinery may 
allow interfering RNA molecules to accumulate at higher 
levels in the yeast. It therefore seems logical to consider the 
development of such systems. Although S. cerevisiae lacks 
Dicer, it does have one RNAse III gene, Rntp1 [56, 57]. 
While we were able to produce shRNA in yeast in the pres-
ence of a functional copy of this gene [9, 10], the hairpin 
loop used in our studies is not recognized by Rntp1 [58-61]. 
Depending on the interfering RNA molecule produced, it 
may be useful in some cases to modify the levels of this 
gene. It would be interesting to recapitulate the Huang et al. 
[53] p19 system in S. cerevisiae, and doing so should be 
fairly straightforward. Recombinant p19 could be expressed 
in yeast, and larger-scale fermentations in a bioreactor would 
need to be optimized, but are certainly possible. Given the 
lack of RNAi machinery in S. cerevisiae, it is possible that 
fewer endogenous dsRNAs would be available to bind to 
p19, which might result in the isolation of purer recombinant 
dsRNAs that can be produced in E. coli.    
4. PROSPECTS AND CHALLENGES FOR COM-
MERCIAL DEVELOPMENT 
4.1. Overview 
 Due to the many attributes of S. cerevisiae, it is consid-
ered to be an exceptional workhorse for biopharmaceutical 
production [2]. Roughly 20% of today’s biopharmaceuticals 
are produced in yeasts, with S. cerevisiae, the most geneti-
cally developed yeast species, most often selected for pro-
duction purposes [62]. Biopharmaceutical production in 
yeast initiated in the 1980s when ZymoGenetics, the first 
company to succeed in the industrialization of S. cerevisiae 
for production of pharmaceuticals, engineered yeast that 
produced recombinant human insulin. Today, nearly half the 
global supply of insulin is produced in S. cerevisiae [21]. In 
the 1990s, S. cerevisiae-based production of a hepatitis B 
subunit vaccine, recombinant human granulocyte macro-
phage-colony stimulating factor, and human platelet derived 
growth factor followed, as did the production of the human 
papillomavirus subunit vaccine and a kallikrein inhibitor, all 
of which were produced after the turn of the century [21]. 
The uptake of yeast by immune cells combined with the ease 
of producing pathogens and tumor antigens in yeast cells has 
resulted in the use of yeasts as a new vaccine platform [2]. In 
particular, the potential for using whole yeast vaccines for 
oral immunization strategies is gaining momentum [2, 63]. 
Thus, a strong history of using yeast for production of bio-
pharmaceuticals suggests that this platform could be used for 
the production of shRNA-based biopharmaceuticals and bio-
pesticides. 
 Following development of the initial concept and selec-
tion of target molecules in microbes, the process of bioengi-
neering strains for production of commodity chemicals in-
volves the characterization of target molecule expression and 
optimization of expression levels, overcoming any toxicity 
that may develop in the host strain, optimizing host metabo-
lism to enhance biomolecule production, and scale-up of the 
production to commercial reactors [64] (Fig. 1). The CD40 
silencing and mosquito pesticide studies discussed above 
illustrate that target molecules selection and expression can 
be achieved in S. cerevisiae. However, the path from target 
shRNA molecule selection and initial engineering of shRNA 
expression strains to scaled production of commercial vol-
umes is less clear. As noted above, S. cerevisiae has been 
used to produce a number of commercially manufactured 
biopharmaceuticals [20]. Unfortunately, none of these prod-
ucts were RNA products, and so optimized and scaled pro-
duction of interfering RNA molecules in S. cerevisiae will 
likely require considerable research and development.  
 Chubukov et al. [64] discuss the challenges of using syn-
thetic and systems biology for producing commodity chemi-
cals in microbes, and many of their findings may be applica-
ble to the development of recombinant yeast-interfering 
RNA expression systems. The authors explain that to date, 
the production of biomolecules by microbes has largely fo-
cused on pharmaceutical production, as these molecules will 
enter high-price low-volume markets where they have a 
higher likelihood of making a more immediate and tangible 
impact [65]. However, as more of these molecules are suc-
cessfully developed, both the need and the potential for pro-
ducing high-volume and low-cost molecules, such as biopes-
ticides, will likely grow. In either case, the commercial po-
tential of these molecules must be assessed, typically during 
the development phase prior to scale-up, but this is not an 
easy task. The development of reasonable estimates requires 
knowledge of the chemical properties and efficacy of the 
product, as well as assessment of the price and feasibility of 
producing the biomolecules by microbes at scale. Likewise, 
it relies on the ability to predict additional developmental 
costs required for scale-up, as well as down-stream purifica-
tion costs. Such predictions are difficult at best but will 
likely become more straightforward as the volume of suc-
cessful biomolecule production schemes developed in S. 
cerevisiae increases [64]. Given the many potential applica-
tions of yeast-interfering RNA technology, optimization of 
the scaled production of interfering RNA molecules in yeast 
could yield high dividends, but it is very difficult at this 
juncture to estimate the costs of successfully scaling and 
commercializing this technology. Moreover, although some 
parameters will undoubtedly vary depending on the interfer-
ing RNA molecules to be produced for each given applica-
tion, investment into the optimization of this process for sev-
eral recombinant RNA-producing yeast strains is likely to be 
broadly applicable to many different RNA-based bio-
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molecule production schemes in yeast. Given the potential 
benefits, some of the key areas that will need to be devel-
oped will now be discussed.  
4.2. Optimizing shRNA Production in S. cerevisiae 
 Although S. cerevisiae lacks recognizable orthologs of 
both Dicer and Argonaute, introduction of these proteins into 
S. cerevisiae generates RNAi activity [3] (Table 1). Using S. 
cerevisiae in which RNAi machinery had been reconstituted 
through heterologous expression of Argonaute and Dicer, 
Crook et al. [15] worked to optimize yeast as a metabolic 
engineering tool (Table 1). Their overall goal was to use 
RNAi to identify genetic targets that can be modulated to 
improve yeast strains used for synthesis of various biological 
molecules, but their findings may also be applicable more 
generally to the commercialization of dsRNA molecule pro-
duction in yeasts. To begin to optimize their yeast shRNA 
expression system, the authors evaluated how hairpin ex-
pression levels, hairpin length, and copy number of the hair-
pin expression plasmid influenced target gene silencing. A 
yellow fluorescent protein (YFP) gene that had been artifi-
cially expressed in yeast cells served as the target gene in 
these studies, as detection of YFP fluorescence readout per-
mitted straightforward monitoring of gene silencing. In-
creased downregulation of YFP fluorescence levels was ob-
served when the shRNA was expressed from a strong 
pTDH3 promoter as opposed to a weak pCYC1 promoter, 
with 80% downregulation of YFP expression observed when 
the strong promoter drove shRNA expression. They also 
observed an increase in gene silencing when the hairpin 
length was increased from 100 to 200 bp. Expression of a 
200 bp shRNA with the strong promoter resulted in 94% 
downregulation of YFP fluorescence, though the authors 
reported difficulty in construction and propagation of strains 
with an inverted repeat of this size. They suspected that the 
problem might be the result of interference with DNA repli-
cation machinery [66], which was resolved through inclusion 
of an intron-containing spacer that increased plasmid stabil-
ity [67].  
 Next, Crook et al. [15] examined the impact of shRNA 
expression plasmid copy number on YFP silencing. Yeast 2 
μ-based plasmids, which are maintained at copy numbers of 
5-30 per cell in in S. cerevisiae, can facilitate high transgene 
expression levels, but these plasmids can be difficult to 
maintain and may be less stable [68]. Centromeric plasmids 
are another option; these plasmids bear an autonomously 
replicating origin and a yeast centromere, but only a single 
copy is present in each yeast cell [69], making it difficult to 
promote high expression levels [68]. After exploring the use 
of several different vectors, Crook et al. [15] determined that 
silencing was improved through the use of a low copy 
auxotrophic TRP1 marker vector that enabled 93% down-
regulation of YFP fluorescence, though they ultimately con-
cluded that a mechanism other than copy number was re-
sponsible for the improved silencing observed when using 
low copy auxotrophic vectors in their assays. Another option 
that was not explored by Crook et al. [15], but that was re-
cently used in our own yeast interfering RNA system [9], is 
to stably integrate expression cassettes into the yeast genome 
by coupling integration with selection of a deficient marker. 
Although several multiple integration approaches have been 
developed, there is not always a linear correlation between 
copy number and yield [68]. Indeed, we have not observed 
higher levels of interfering RNA larvicide activity in strains 
in which the copy number was increased from two to four 
copies of the integrated RNA expression cassette (MDS, 
unpublished). 
 After optimizing their system, Crook et al. [15] were able 
to quickly use RNAi for improvement of itaconic acid pro-
duction in S. cerevisiae. More recently, the development of 
S. cerevisiae dsRNA expression libraries has facilitated tun-
able RNAi screens aimed at optimizing yeast biomolecule 
production systems through RNAi-assisted genome engi-
neering [16, 17] (Table 1). These systems will make it possi-
ble to use RNAi to optimize expression of a wide variety of 
therapeutics, such as insulin and vaccines, in yeast. The re-
sults of this study may also have implications for the use of 
yeast-shRNA expression systems for the silencing of genes 
Fig. (1). Pathway to commercialization of yeast interfering RNA bioreagent technology. 
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in humans or insects, though it is difficult to know how well 
the results will translate to improved silencing efficiency in 
non-yeast cells. It should also be noted that silencing effi-
cacy must be optimized for each separate target gene, and so 
the results of YFP gene silencing studies may not be applica-
ble to every target gene in yeast or non-yeast cells.  
 Rather than cloning shRNA expression cassettes, when 
their RNAi screening libraries were produced, both Si et al. 
[16] and Crook et al. [17] used a different approach for pro-
duction of dsRNA in yeast. Both groups opted to clone 
larger pieces of yeast DNA (i.e. 200-400 bp fragments) be-
tween converging reporters that were used for production of 
dsRNA corresponding to the sequence cloned between the 
two promoters. A similar approach was recently used by 
Muprhy et al. [14] to produce yeast-based dsRNA insecti-
cides for control of Drosophila pest species (Table 1). These 
longer pieces of dsRNA induced efficient gene silencing 
both in yeast and in Drosophila. Crook et al. [17] made an 
effort to optimize RNAi efficiency when they constructed 
their libraries. Using their YFP expression system to evalu-
ate RNAi efficacy, they determined that the addition of in-
trons improved downregulation of YFP. They again found 
that use of a low-copy vector actually significantly improved 
YFP downregulation as it had in their previous shRNA study 
[15]. Although comparisons of silencing rates induced by 
shRNA vs. dsRNA have yet to be performed, cloning longer 
dsRNA molecules is undoubtedly more straightforward that 
cloning shRNA expression cassettes and therefore much 
more suitable for construction of whole yeast genome RNAi 
screening libraries. Moreover, examining the expression lev-
els of shRNAs that are very short in length, such as those 
used in the Hapairai et al. [9] and Mysore et al. [10] studies, 
is extremely difficult. Due to the secondary structure of these 
molecules, it is difficult to PCR-amplify cDNA prepared 
from shRNA or to detect it with Northern blots. In these 
cases [9, 10], measure of RNAi efficacy required examina-
tion of target gene RNA transcript levels, which were re-
duced by ~90%. This issue could be resolved by the use of 
longer shRNA molecules, such as those used by Zhang et al. 
[13], the levels of which could be directly monitored by 
qRT-PCR.  
 The use of inducible promoters for expression of RNA 
should also be explored further. In our study [9], although 
shRNA expression was initially under control of a constitu-
tive promoter, expression of shRNA was placed under an 
inducible Gal1 promoter when the shRNA expression cas-
settes were integrated into the yeast genome. We reasoned 
that use of this promoter would be necessary when the ex-
pression cassettes were stably integrated, as it could poten-
tially make up for the lower copy number (initially one, and 
then increased to two) of the integrated expression cassettes. 
This did appear to be the case, as the copy number was re-
duced ~10 fold, but comparable larvicide activities resulted. 
However, it has been argued that the use of galactose for 
induction of gene expression is not realistic for large-scale 
industrial fermentations, as production is complicated by the 
requirement to use galactose as the carbon source, and galac-
tose is more expensive than glucose [70]. Also, a lack of 
Gal1 promoter induction has been observed when the carbon 
source is switched from glucose to galactose under anaerobic 
conditions [71, 72]. It may therefore be advisable to choose 
other promoters, and assessment of promoters that may be 
more readily used in industrial-sized cultures will be impor-
tant. 
 Clearly, although much work has been undertaken and 
significant strides were made, much more work could be 
pursued to define the best parameters for production of inter-
fering RNA in yeast. For example, future studies should di-
rectly compare the efficacy of shRNA vs. longer dsRNA 
yeast expression systems. Parameters such as the duration of 
target gene silencing, dsRNA half-life, and propensity for 
off-site targeting should also be included in these compara-
tive studies. These parameters are quite likely to change de-
pending on the gene being studied and the organism in which 
the yeast will ultimately be used, and so it will be useful to 
collect data for multiple transgenes and in different tissues.  
4.3. Scaling Yeast Production 
 Recent advances in molecular genetics, systems and syn-
thetic biology have revolutionized the potential for advanc-
ing yeast biosynthetic systems. Further advancement of this 
potential into commercial production requires scaling pro-
duction from lab cultures sizes (i.e. one ml to one L culture 
volumes) to industrial scaled commercial biorecators (i.e. 
one hundred to one million L volumes). Unfortunately, 
promising strategies that work well in the laboratory do not 
always directly scale well under industrial fermentation con-
ditions or are not robust enough to withstand changes in sys-
tem parameters [64]. Chubukov et al. [64] comment that 
implementation of ideas in biological engineering requires 
significantly more effort than creating them and can require 
5-10 years for further development and optimization of the 
process. A difficulty in predicting the behavior of large-scale 
fermentations is at the root of this problem [73], underscor-
ing the utility of piloting scaled production during early 
phases of a project. 
 As discussed by Chubukov et al. [64], a variety of factors 
can contribute to difficulties in scale-up, resulting in reduced 
yields of the desired product, undesired side products, and 
problems with batch consistency. In particular, production 
schemes that exhibit susceptibility to minor variations in 
cultivation conditions in the laboratory or which cannot be 
easily reproduced within or between laboratories are not 
likely to fare well when scaled [64]. Physiological and meta-
bolic states can be different in large versus small scale cul-
tures, leading to altered growth rates. Challenges in mixing 
associated with large bioreactors can result in non-
homogenous conditions, with gradients of glucose and oxy-
gen leading to poor yields as a result. Re-optimizing cultur-
ing conditions, including pH, aeration, and carbon source 
feeding rates may therefore be necessary when production 
size is increased [68]. Chubukov et al. [64] also emphasize 
that it is important to identify optimal flux distributions by 
manipulating host metabolism to direct as much flux as pos-
sible to production of the desired product. As discussed 
above, dsRNA screening libraries have led to the identifica-
tion of genetic factors that could be manipulated to improve 
production of desired products in S. cerevisiae [16, 17]. Now 
that these screening libraries have been constructed, such 
strategies, which result directly from the genetic tractability 
of this species, are likely to be invoked more frequently and 
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promise to have a profound impact on the yeast biomolecule 
production industry.  
 While toxicity of the product to the host strain can be a 
problem in yeast cultures of any size, toxicity is often a prob-
lem at the scale-up stage [64]. Toxicity, which has primarily 
been studied in the context of recombinant protein produc-
tion, could also be problematic when dsRNA molecules are 
expressed at high levels in yeast. The lack of native RNA 
machinery in S. cerevisiae could offer some protection 
against dsRNA toxicity, though non-processed dsRNA could 
potentially have cytotoxic effects as well. However, though 
we have constructed and characterized many different 
shRNA expression strains in our laboratory [9, 10] (MDS 
unpublished), we have not yet noticed any significant toxic-
ity in these strains. However, it should be noted that we have 
not yet scaled culture sizes to more than 1 L in volume. In-
terestingly, the LD50 and LD90 values for most of the yeast 
interfering RNA larvicide strains produced by our group to 
date are fairly comparable (MDS, unpublished). It is there-
fore possible that some sort of negative feedback on shRNA 
production in yeast, shRNA stability in yeast, processing of 
shRNA, or the silencing of target genes in insect cells, may 
exist. When toxicity results from protein production in S. 
cerevisiae, problems with strain toxicity are often addressed 
through manipulation of transcriptional control, which is 
highly modular and well characterized in this species 
[Chubukov, 2016 #70]. Given that the goal will be to pro-
duce RNA rather than protein as a product, the wealth of 
knowledge regarding transcriptional regulation in S. cere-
visiae will be an asset for overcoming toxicity issues that 
might arise when RNA is produced in yeast. Finally, in addi-
tion to considering toxicity of the RNA to the yeast strain, 
when developing yeast interfering RNA strains for commer-
cialization, it is of course also critical to evaluate the poten-
tial toxicity of these strains to humans or other non-target 
organisms. This review has touched upon several efforts to 
improve the safety of this technology (i.e. heat-inactivation 
of yeast, generation of stable transformants that eliminate the 
need for use of plasmids with antibiotic resistance markers). 
While this subject is much broader than the scope of this 
review, it is nevertheless a critical aspect of evaluating the 
commercial potential of yeast interfering RNA technology.  
4.4. Considerations for Drying and Encapsulation 
 Beyond scaling yeast production, if recombinant yeast is 
to be produced in formulations that can be consumed by hu-
mans or used to treat containers in which mosquitoes are 
breeding, the yeast will need to be formulated, packaged, 
shipped, and stored, all the while maintaining the integrity of 
the recombinant interfering RNA molecules (Fig. 1). Based 
on our success with dried and inactivated yeast interfering 
RNA larvicides (Fig. 2A), we anticipate that the desired end 
product is an inactivated, dried, ready-to use tablet. Given 
that the tablets we produced [9, 10] were modeled after yeast 
nutritional tablets, a human dietary supplement, it is quite 
possible that a similar preparation could be used for human 
gene therapy applications. Likewise, one could envision that 
a similar formulation could be used for whole yeast vaccine 
applications [2, 63] or for the delivery of mRNA, DNA, or 
proteins to intestinal DC cells [27, 30-32], and so further 
development of this technology could have multiple applica-
tions (Fig. 2B). Unfortunately, our current procedure for 
generating dried inactivated tablets is a laborious process 
that produces only several tablets at a time (Fig. 2A) [9, 10]. 
Clearly, the process of producing dried inactivated yeast 
tablets will need to be scaled for commercial production. 
 Modern food drying technologies for processing natural 
compounds aim to effectively dry the materials while main-
taining high concentrations of bioactive compounds [74]. 
Freeze drying is a popular method of preserving microbial 
cultures and is often used for the preservation of live yeast 
strains that are heat-labile [75]. However, it is a somewhat 
expensive and laborious process, and the hygroscopic prod-
uct can pick up moisture from the atmosphere [76]. Fluidized 
bed drying is cost effective and has been successfully used to 
produce products in the food, pharmaceutical, and agricul-
tural industries [74]. This system has many advantages, in-
cluding high drying rates and high thermal efficiency, and it 
has been used to dry yeast without significant loss of vita-
mins [74]. Spray drying, which may increase product shelf 
life, has also been explored in yeast [74, 76]. The spray dry-
ing method is widely used because it is cost-effective, en-
hances evaporation of liquids, and is readily scaled [74]. 
Spray drying at lower temperatures (i.e. 40 – 60o C) has led 
to better preservation of a number of biological compounds 
[74, 77], and this is likely to be the case for RNA molecules, 
as well. It is not presently known whether dsRNA or shRNA 
expressed in yeast withstands any of these drying processes, 
and so it will be critical to explore this concept further. Fol-
lowing drying, methods for large-scale tableting of the dried 
yeast will also need to be employed.  
 Although we have recently succeeded in the development 
of yeast interfering RNA tablets (Fig. 2A) that are stable at 
room temperature for at least two weeks (MDS, unpub-
lished), shelf life stabilities of 1-2 years are more typical for 
commercial products. Moreover, exposure to extreme tem-
peratures and variable humidity conditions is common when 
materials are shipped, and the final formulation must be sta-
ble under such conditions. It is therefore critical that packag-
ing and storage conditions are optimized in preparation for 
commercialization (Fig. 1). Encapsulation of yeast may offer 
some protection against environmental conditions [76]. Fur-
thermore, encapsulation can also help facilitate controlled 
release of microorganisms [78], which is likely useful given 
that time-release yeast interfering RNA formulations will 
likely be preferred for both medical and mosquito control 
applications. A wide range of food grade materials have been 
developed for microencapsulation and controlled release 
technologies applied to tableted preparation [76, 78, 79]. The 
development of methods for microencapsulation and time-
release formulation of yeast has grown in recent years, as 
interest in the use of yeast probiotics has increased [79]. Al-
though yeast used in probiotic applications must be viable, 
which may not be necessary for yeast RNA delivery systems 
(see above), these studies may nevertheless be of interest for 
RNA delivery applications and would likely benefit from 
further research in this area (Fig. 2). Alginate-chitosan mi-
croencapsulation of Saccharomyces has been explored in 
recent studies [80, 81]. The use of chitosan is of interest, as 
chitosan itself can also be used for delivery of dsRNA/ 
siRNA molecules [45, 82, 83], and the potential to combine 
yeast and chitosan delivery systems is intriguing. Jantzen  
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et al. [84] explored the use of whey as a bacterial substrate 
and encapsulation matrix within a coupled fermentation and 
spray drying process, concluding that this technology is an 
efficient method for industrial production of probiotics. 
Thus, many potential agents for microbial encapsulations are 
available, and this will be a critical area of exploration for 
improvement of yeast RNA delivery systems. 
CONCLUSION 
 In conclusion, S. cerevisiase may be an excellent system 
for production and delivery of interfering RNA molecules, 
and the development of yeast in this capacity clearly has 
many potential applications of medical importance. This 
review has highlighted the many advantages of the S. cere-
visiae system, while also outlining key areas that will require 
further research and development. We have only begun to 
explore how to optimize shRNA and dsRNA expression lev-
els in yeast, and more work must be pursued, particularly in 
industrial-scaled cultures. It will be critical to pilot larger-
scaled culturing of yeast interfering RNA production strains 
in the near future. This will help us examine the potential for 
culturing these strains at industrial-sized scale and to under-
stand how the strains and their growth conditions can be fur-
ther optimized in preparation for commercial-scale produc-
tion. Moreover, it will be critical to develop scaled methods 
for drying yeast that preserve the integrity of the interfering 
RNA molecules. The identification of encapsulating agents 
that promote yeast stability in various environmental condi-
tions, both prior to and during its use, as well as to facilitate 
the controlled release of yeast will also be key. As discussed 
by Chubukov et al. [64], the implementation of ideas in bio-
logical engineering can sometimes require significantly more 
effort than the creation of these ideas. Thus, while this tech-
nology shows a great deal of promise in the laboratory, a 
good deal more work will be required for the successful 
commercialization of this technology. The genetic tractabil-
ity of S. cerevisiae and the long history of using this microbe 
in both the food and pharmaceutical industry will undoubt-
edly benefit the development of this microbe as a production 
and delivery system for interfering RNA molecules. 
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Fig. (2). Potential applications for dried encapsulated yeast tablets. (A) A dried inactivated yeast tablet prepared as described [9, 10] is shown 
at top; a penny is shown for scale below it. (B) Delivery of interfering RNA, mRNA, or proteins through yeast requires the development of 
dried encapsulated tablet formulations. The development of whole yeast vaccines and yeast probiotic therapeutics would also benefit from 
research and development on yeast encapsulation and drying. 
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